• 23. Dezember 2024

ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab

ByISA Pharmaceuticals

Dez 7, 2015
– Trial in patients with HPV16-positive, incurable solid tumors initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb
Teile den Beitrag mit Freunden